688185.SH
康希诺
SSE · Healthcare · Biotechnology · CN
CNY 75.50
−2.35%Year over year
Reported trailing growth
- Revenue
- +29.0%
- EBITDA
- —
- EBIT
- +102.8%
- EPS
- +100.2%
- Free cash flow
- +63.4%
- Operating cash flow
- +151.8%
Forward estimates
Based on analyst estimates
- Revenue
- -20.8%
- EBITDA
- +48.2%
- EPS
- —
Three-year CAGR
- Revenue
- +1.1%
- EBITDA
- +212.3%
- EBIT
- +106.4%
- Net income
- +107.4%
- EPS
- +107.2%
- Free cash flow
- +75.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026